Literature DB >> 29568954

Tranilast prevents renal interstitial fibrosis by blocking mast cell infiltration in a rat model of diabetic kidney disease.

Dan-Dan Yin1, Jun-Hui Luo1, Zhu-Ye Zhao1, Ying-Jun Liao1, Ying Li1.   

Abstract

Renal interstitial fibrosis is a final pathway that is observed in various types of kidney diseases, including diabetic kidney disease (DKD). The present study investigated the effect of tranilast on renal interstitial fibrosis and the association between its role and mast cell infiltration in a rat model of DKD. A total of 30 healthy 6‑week‑old male Sprague‑Dawley rats were randomly divided into the following four groups: Normal control group; DKD model group; low‑dose tranilast group (200 mg/kg/day); and high‑dose tranilast group (400 mg/kg/day). The morphological alterations of tubulointerstitial fibrosis were evaluated by Masson's trichrome staining, while mast cell infiltration into the renal tubular interstitium was measured by toluidine blue staining and complement C3a receptor 1 (C3aR) immunohistochemical staining (IHC). The expression of fibronectin (FN), collagen I (Col‑I), stem cell factor (SCF) and proto‑oncogene c‑kit (c‑kit) was detected by IHC, western blotting and reverse transcription‑quantitative‑polymerase chain reaction. The results demonstrated that tubulointerstitial fibrosis and mast cell infiltration were observed in DKD model rats, and this was improved dose‑dependently in the tranilast treatment groups. The expression of FN, Col‑I, SCF and c‑kit mRNA and protein was upregulated in the tubulointerstitium of DKD model rats compared with the normal control rats, and tranilast inhibited the upregulated expression of these markers. Furthermore, the degree of SCF and c‑kit expression demonstrated a significant positive correlation with C3aR‑positive mast cells and the markers of renal interstitial fibrosis. The results of the present study indicate that mast cell infiltration may promote renal interstitial fibrosis via the SCF/c‑kit signaling pathway. Tranilast may prevent renal interstitial fibrosis through inhibition of mast cell infiltration mediated through the SCF/c-kit signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29568954     DOI: 10.3892/mmr.2018.8776

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  8 in total

1.  Downregulation of hepatic stem cell factor by Vivo-Morpholino treatment inhibits mast cell migration and decreases biliary damage/senescence and liver fibrosis in Mdr2-/- mice.

Authors:  Vik Meadows; Lindsey Kennedy; Laura Hargrove; Jennifer Demieville; Fanyin Meng; Shohaib Virani; Evan Reinhart; Konstantina Kyritsi; Pietro Invernizzi; Zhihong Yang; Nan Wu; Suthat Liangpunsakul; Gianfranco Alpini; Heather Francis
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-09-13       Impact factor: 5.187

Review 2.  Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy.

Authors:  Sandra Rayego-Mateos; José Luis Morgado-Pascual; Lucas Opazo-Ríos; Melania Guerrero-Hue; Cristina García-Caballero; Cristina Vázquez-Carballo; Sebastián Mas; Ana Belén Sanz; Carmen Herencia; Sergio Mezzano; Carmen Gómez-Guerrero; Juan Antonio Moreno; Jesús Egido
Journal:  Int J Mol Sci       Date:  2020-05-27       Impact factor: 5.923

3.  Renal tubular epithelial cells: the neglected mediator of tubulointerstitial fibrosis after injury.

Authors:  Ruochen Qi; Cheng Yang
Journal:  Cell Death Dis       Date:  2018-11-13       Impact factor: 8.469

Review 4.  The Role of Inflammasome-Dependent and Inflammasome-Independent NLRP3 in the Kidney.

Authors:  Yang Gyun Kim; Su-Mi Kim; Ki-Pyo Kim; Sang-Ho Lee; Ju-Young Moon
Journal:  Cells       Date:  2019-11-05       Impact factor: 6.600

5.  Tranilast inhibits angiotensin II-induced myocardial fibrosis through S100A11/ transforming growth factor-β (TGF-β1)/Smad axis.

Authors:  Youquan Chen; Ming Huang; Yi Yan; Dequan He
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

6.  Iguratimod alleviates tubulo-interstitial injury in mice with lupus.

Authors:  Leixi Xue; Jiajun Xu; Wentian Lu; Jinxiang Fu; Zhichun Liu
Journal:  Ren Fail       Date:  2022-12       Impact factor: 2.606

Review 7.  Nephrotoxicity of Herbal Medicine and Its Prevention.

Authors:  Xiaofen Xu; Ruyi Zhu; Jialiang Ying; Mengting Zhao; Xin Wu; Gang Cao; Kuilong Wang
Journal:  Front Pharmacol       Date:  2020-10-15       Impact factor: 5.810

Review 8.  Mast Cells in Diabetes and Diabetic Wound Healing.

Authors:  Jie Dong; Lihong Chen; Ying Zhang; Navin Jayaswal; Ikram Mezghani; Weijie Zhang; Aristidis Veves
Journal:  Adv Ther       Date:  2020-09-15       Impact factor: 3.845

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.